CClinicalTrials.gg
CompletedNCT04577170Updated Nov 9, 2023

Pulsatility Index, Vasomotor Reactivity and Leukoencephalopathy in Fabry Patients

An observational study in Fabry Disease, sponsored by National and Kapodistrian University of Athens. Completed at 1 site in Greece. Open to participants aged 16 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by National and Kapodistrian University of Athens · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
45
Ages
16 Years to 70 Years
Sex
All
01

Study summary

We hypothesize that Fabry disease - FD is associated with elevated vascular resistance induced by cerebral small-vessel disease, indicating increased distal resistance to blood flow. The findings of this study may be used as a precursor for neuroimaging manifestations related to stroke in FD patients.

02

Conditions studied

  • Fabry Disease

Keywords

  • pulsatility index
  • vasomotor reactivity
  • leukoencephalopathy
  • transcranial ultrasound
03

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Consecutive patients with genetically confirmed FD and healthy individuals will be prospectively enrolled as part of routine clinical examination.

Inclusion criteria

Fabry disease diagnosis, genetically confirmed Age> 16 years

Exclusion criteria

Exclusion Criteria:

Insufficient temporal bone window MRI contra-indication Inability to cooperate for breath-holding test Detection of atrial fibrillation Refuse to sing informed consent

04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
45 participants (actual)
Patient registry
No

Groups and cohorts

  • Fabry disease

    Diagnostic Test: Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography

  • Healthy

    age and sex matched

    Diagnostic Test: Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography

Interventions

  • Diagnostic testTranscranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography

    Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.

05

What researchers measure

Primary outcomes

  1. Prevalence of elevated pulsatility index of FD patients

    to assess the prevalence of elevated pulsatility index in FD patients at a single time point.

    Time frame: 2 years

  2. Prevalence of elevated vasomotor reactivity in FD patients.

    to assess the prevalence of elevated vasomotor reactivity in FD patients at a single time point.

    Time frame: 2 years

Secondary outcomes

  1. Association of pulsalitily index with leukoencephalopathy in FD patients.

    To associate the pulsality index measured by TCD and TCCD with the presence of white matter lesions in brain MRI of FD patients.

    Time frame: 2 years

  2. Association of vasomotor reactivity with leukoencephalopathy in FD patients.

    To associate the vasomotor reactivity measured by TCD and TCCD with the presence of white matter lesions in brain MRI of FD patients.

    Time frame: 2 years

  3. Τo compare the pulsatility index measured in FD patients against corresponding prospectively collected data from healthy individuals, stratified by age and sex.

    For the secondary outcome, age and sex-matched healthy controls will be consecutively enrolled. After clinical evaluation, healthy controls will present no FD-associated manifestations, hence they will be FD negative. In addition, brain MRI will be performed and subjects with white matter disease and leukoencephalopathy will be excluded. Included controls will be leukoencephalopathy negative. TCD and TCCD evaluation will be performed in healthy controls, in order to measure pulsatility index and compare the results against FD patients.

    Time frame: 2 years

  4. Τo compare vasomotor reactivity measured in FD patients against corresponding prospectively collected data from healthy individuals, stratified by age and sex.

    For the secondary outcome, age and sex-matched healthy controls will be consecutively enrolled. After clinical evaluation, healthy controls will present no FD-associated manifestations, hence they will be FD negative. In addition, brain MRI will be performed and subjects with white matter disease and leukoencephalopathy will be excluded. Included controls will be leukoencephalopathy negative. TCD and TCCD evaluation will be performed in healthy controls, in order to measure vasomotor reactivity and compare the results against FD patients.

    Time frame: 2 years

06

Study locations

1 site
  • Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
    Athens, 12462, Greece
07

Registry details

Key details

Study ID
NCT04577170
Lead sponsor
National and Kapodistrian University of Athens
Responsible party
Georgios Tsivgoulis (Professor, National and Kapodistrian University of Athens) — Principal investigator
First posted
Oct 6, 2020
Start date
Nov 20, 2020
Primary completion
Jul 1, 2022
Completion
Jan 20, 2023
Last update
Nov 9, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion